相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
Tadeusz Robak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A review of monoclonal antibody therapies in lymphoma
Esmeralda Chi-yuan Teo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia
Tadeusz Robak et al.
SEMINARS IN ONCOLOGY (2016)
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant/relapse-initiating CLL cells: a rationale for combination treatment
S. Betrian et al.
BLOOD CANCER JOURNAL (2016)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Tetraspanin CD37 Regulates β2 Integrin-Mediated Adhesion and Migration in Neutrophils
Janet L. Wee et al.
JOURNAL OF IMMUNOLOGY (2015)
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Daniel S. Pereira et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR (TM) therapeutic protein, for relapsed or refractory NHL patients
John M. Pagel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Advances in the treatment of hematologic malignancies using immunoconjugates
Maria Corinna Palanca-Wessels et al.
BLOOD (2014)
Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies
Piotr Smolewski et al.
EUROPEAN JOURNAL OF CANCER (2014)
Anti-CD37 antibodies for chronic lymphocytic leukemia
Tadeusz Robak et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients
Ajay K. Gopal et al.
INVESTIGATIONAL NEW DRUGS (2014)
Tetraspanins at a glance
Stephanie Charrin et al.
JOURNAL OF CELL SCIENCE (2014)
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art
Tadeusz Robak
EXPERT REVIEW OF HEMATOLOGY (2014)
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
Jutta Deckert et al.
BLOOD (2013)
Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration
Kate H. Gartlan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies
Sarwish Rafiq et al.
MABS (2013)
Biodistribution and Dosimetry of Lu-177-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
Ada H. V. Repetto-Llamazares et al.
CURRENT RADIOPHARMACEUTICALS (2013)
Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
Rosa Lapalombella et al.
CANCER CELL (2012)
A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
Karl-Heinz Heider et al.
BLOOD (2011)
A Complementary Role for the Tetraspanins CD37 and Tssc6 in Cellular Immunity
Kate H. Gartlan et al.
JOURNAL OF IMMUNOLOGY (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC
Kuo-Ching Sheng et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Xiaobin Zhao et al.
BLOOD (2007)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation
S Barrena et al.
LEUKEMIA (2005)
A regulatory role for CD37 in T cell proliferation
AB van Spriel et al.
JOURNAL OF IMMUNOLOGY (2004)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions
KP Knobeloch et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
